Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody
Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio , a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the preclinical results for MRT5500, a mRNA-based vaccine candidate against SARS-CoV-2, the virus that causes COVID-19 disease.
Preclinical evaluation of MRT5500, importantly, demonstrated a favorable immune response profile against SARS-CoV-2. These data support the selection of MRT5500 for clinical development. A Phase 1/2 clinical trial is anticipated to begin in the fourth quarter of 2020. Full results are available here. MRT5500 is being developed under a collaboration agreement between Sanofi Pasteur and Translate Bio.
CPhI Worldwide to return in 2021
You May Interested In
China Top quality etizolam 99.9% white powder CAS 125541-22-2 WPF
$10000-10200/KG EXW
China hot sale MDA 19 99.9% Yellow powder mda19/5f ad18 WPF
$4800-5000/KG EXW
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
What Other Vaccines Use mRNA And The Application Of Homogeneous Technology In mRNA Vaccine And Drug Development.
-
Does Vaccine Protect Against Omicron? Zhang Wenhong : Vaccination Booster Is Still An Effective Tool To Deal With Omicron
-
Shanghai Company's Self-Developed COVID-19 mRNA Vaccine Approved For Clinical Trials And mRNA Vaccines Animal Trials
-
mRNA Vaccine Production Process : LNP Delivery Technology
-
New crown test reagents collected in 18 provinces, fill in the lowest price in the country
-
The First Time To Interrupt The Chain Of Virus Transmission! Cai Qi Hosted a Meeting To Dispatch The Disposal Of The Epidemic
-
The New Crown Antigen Self-Testing Products Were Approved For Marketing Who Can Self-Test?
-
The Final Effective Rate Of Pfizer's Oral New Covid Drug Is 89%
-
New COVID-19 drug nears approval in Australia
-
Virus that causes COVID-19 can find alternate route to infect cells
Recommend Reading
-
Can an antibody 'cocktail' prevent COVID-19 infection?
-
J&J Suspends Covid-19 Vaccine Study, Vaccinators Show Unspecified Symptoms
-
The First TCR-T Product For The Treatment of Liver Cancer Was Approved For Clinical Use
-
Potential COVID-19 vaccines not affected by dominant 'G-Strain'
-
New Drug Approvals
-
Carlyle acquires 37% of Spain’s Cepsa, appoints CEO
-
Foreign trade: 90% of the disappeared orders are back
-
DOP Guide: Continuation of Domestic DOP Market Downward Trend on July 19
-
DOP Guide: Domestic DOP Market Disadvantaged Downward on August 9
-
Azelis/Roquette China expands distribution cooperation, adding plant protein/functional starch/fiber